ERIS Lifesciences Ltd

- Eris Lifesciences intends to maintain discipline on debt levels, targeting a hard stop with net debt in the range of 2 to 2.3 times EBITDA and not exceeding that. - For the Swiss Parenterals acquisition, Rs. 200 crores of the purchase consideration will be funded via debt financing. - Rs. 437.5 crores of Non-Convertible Debentures (NCDs) with 8% coupon rate (redeemable after one year) are issued by Eris Lifesciences to sellers as part of the Swiss Parenterals deal financing. - Promoters have also infused cash to minimize additional debt on Eris' balance sheet. - There is no clear indication of new equity fundraising; focus remains on disciplined capital allocation and prudent calls on mergers and acquisitions. - The company assures prudent capital management without excitement or adrenaline in acquisitions and prioritizes capital discipline.

- For the Swiss Parenterals business, Eris does not currently foresee a need for significant additional capital investment over the next 3-4 years to achieve growth targets; the business is largely capable of taking itself forward as it stands. (Page 20) - Eris plans to invest in expanding Swiss Parenterals’ product range, dossier portfolio, and market coverage, especially in Small Volume Parenterals and RoW markets leveraging Swiss’s channel and Eris’s oral solid manufacturing capability. (Page 5) - Gross block addition related to the Swiss Parenterals deal is estimated at around Rs. 600-625 crores, comprising both tangible and intangible assets (including dossiers and manufacturing facilities), with depreciation spread over 20 years. (Page 14) - Capex for Eris oral solid manufacturing facilities at Guwahati and Ahmedabad continues, including plans for securing PIC/s approvals to boost RoW exports. (Page 6) - Inorganic growth remains a strategic priority, supported by disciplined M&A and capital allocation policies focused on EBITDA-to-debt ratio limits. (Page 20)

- Eris aims to be a Rs. 5,000 crores revenue company by FY29, reflecting significant medium-term growth ambitions. - The Dermatology business is projected to do well next year, with current annualized sales around Rs. 375 crores and ongoing new product launches. - Swiss Parenterals offers a sizable opportunity with a USD 3.5 billion addressable Indian market and a Rs. 30-40 crores oral solid business expected this year. - Injectables in the oral and sterile segments are key growth drivers; inclusion of the Swiss portfolio is expected to add Rs. 100 crores in the next year, with potential for more from newer products. - Eris expects a 2%-3% market share in injectables in India over time and plans to expand presence in Rest of World (RoW) markets leveraging Swiss. - Growth in emerging therapies (Derma, CNS, Women’s health, Nephrology) continues to outpace the market at 4x rate. - Operating cash flows are projected to exceed Rs. 1,800 crores over the next 3 years, supporting growth investments.

- Eris Lifesciences aims to be a Rs. 5,000 crores revenue company by FY29, indicating strong future growth aspirations. - The company projects operating cash flow exceeding Rs. 1,800 crores over the next three financial years and over Rs. 6,000 crores within 4-5 years, supporting earnings growth. - Q3 FY24 showed a 27% YoY growth in EBITDA and 9% YoY growth in cash EPS for the nine-month period, evidencing solid recent earnings momentum. - The acquired Dermatology business is expected to contribute Rs. 375 crores in sales with EBITDA margins improving to 35%. - Swiss Parenterals acquisition is anticipated to bolster earnings via expanding sterile injectables and RoW market penetration. - The company is maintaining financial discipline, targeting EBITDA to debt ratio below 2.3x to support sustainable profit growth. - Gross margins are improving, with certain acquired portfolios expected to reach ~70% gross margin in near term, enhancing profitability.

- The transcript does not explicitly mention the current or expected order book or pending orders for Eris Lifesciences Limited or Swiss Parenterals. - Focus is primarily on acquisitions, business mix, financial performance, and strategic priorities. - Amit Bakshi highlights cautious capital allocation and prudent M&A strategy, emphasizing saying "no" often, which implies disciplined order intake and expansion. - Discussions around growth from acquired portfolios (e.g., Dermatology, Biocon portfolio) suggest expected revenue ramp-up rather than specific pending order values. - No direct figures or explicit details on order book or pending orders are provided in the available pages.